Heng Zhao

Heng Zhao


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2014 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
MCMing Chen
Ming Chen
JYJun Yang
Jun Yang
LZLei Zhu
Lei Zhu
CZCao Zhou
Cao Zhou
HZHeng Zhao
Heng Zhao
Primary intrathoracic liposarcoma is an extremely rare malignancy as well as a rare histologic subtype of intrathoracic sarcoma. Relatively few reports appear in the world literatures. We explored the clinicopathologic features and prognostic factors of this tumor in this study.

1 March 2016 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
Haitang YangHaitang Yang
Haitang Yang
YSYifeng Sun
Yifeng Sun
FYFeng Yao
Feng Yao
KYKeke Yu
Keke Yu
HGHaiyong Gu
Haiyong Gu
HZHeng Zhao
Heng Zhao

1 January 2016 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
Haitang YangHaitang Yang
Haitang Yang
FYFeng Yao
Feng Yao
JTJicheng Tantai
Jicheng Tantai
YZYang Zhao
Yang Zhao
QTQiang Tan
Qiang Tan
HZHeng Zhao
Heng Zhao

1 March 2016 in Journal of Thoracic Disease
Verified
Journal Article
Closed access
PDF file
FYFeng Yao
Feng Yao
Haitang YangHaitang Yang
Haitang Yang
HZHeng Zhao
Heng Zhao
Background: Surgical treatment is thought to be the most effective strategy for multiple small nodules. However, in general, one-stage bilateral resection is not recommended due to its highly invasive nature. Methods: Clinical records of patients undergoing one-stage bilateral resections of multiple pulmonary nodules between January 2009 and September 2014 in a single institution were retrospectively reviewed. Results: Simultaneous bilateral pulmonary resection by conventional video-assisted thoracic surgery (VATS) was undertaken in 29 patients. Ground glass opacity (GGO) accounted for 71.9% (46/64) of total lesions, including 26 pure GGO and 20 mixed GGO lesions. One case underwent bilateral lobectomy that was complicated by postoperative dyspnea. Lobar-sublobar (L/SL) resection and bilateral sublobar resection (SL-SL) were conducted in 16 and 12 cases, respectively, and most of these cases had uneventful postoperative courses. There was no significant difference with regard to postoperative complications (P=0.703), duration of use of chest drains (P=0.485), between one- and two-stage groups. Mean postoperative follow-up in cases of primary lung cancer was 31.4 (range, 10–51) months. There was neither recurrence nor deaths at final follow-up. Conclusions: Single-stage bilateral surgery in selected cases with synchronous bilateral multiple nodules (SBMNs) is feasible and associated with satisfactory outcomes.

1 July 2018 in Journal of Thoracic Disease
Verified
Journal Article
Closed access
PDF file
XPXufeng Pan
Xufeng Pan
JYJun Yang
Jun Yang
SFShijie Fu
Shijie Fu
HZHeng Zhao
Heng Zhao
Lung transplantation was the ultimate method to treat the end-stage benign lung diseases. Although the lung transplantation has been increasing quickly in the past 30 years, the shortage of donor lung still limited its development. Ex vivo lung perfusion (EVLP) was a promising technique that could provide the platform to preserve, evaluate and repair the donor lung graft. In this article, we give a general review of the development of EVLP, its clinical application and the animal model. With the increasing experience of clinical EVLP, some pre-identified unsuitable donor lungs have been re-evaluated and accepted for transplantation. EVLP have now been considered to be an effective way to expand the donor pool.

1 January 2017 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
LFLiwen Fan
Liwen Fan
Haitang YangHaitang Yang
Haitang Yang
FYFeng Yao
Feng Yao
YZYang Zhao
Yang Zhao
HGHaiyong Gu
Haiyong Gu
HZHeng Zhao
Heng Zhao
Purpose: The therapeutic efficacy of targeted therapy for adenosquamous carcinoma (ASC) of the lung remains unclear and the role of epidermal growth factor receptor (EGFR) testing in patients with ASC also remains controversial. We aimed to analyze the efficacy of EGFR tyrosine kinase inhibitors (EGFR-TKIs) in ASC. Methods: Clinical records of patients with ASC who received treatment with EGFR-TKIs between January 2006 and December 2014 at two institutions were retrospectively reviewed. Results: A total of 27 EGFR mutation-positive patients with ASC who received TKI therapy were enrolled in this study. EGFR mutations included a deletion in exon 19 in 15 cases and a point mutation at codon 858 (L858R) in exon 21 in 12 cases. Among the 27 ASC patients who received treatment with EGFR-TKIs, nine had a partial response and 11 achieved stable disease, accounting for a disease control rate of 74.1% (20/27). The median postoperative overall survival (OS) of the EGFR-mutant patients who received TKI therapy was 39 months (95% confidence interval [CI]: 25.6–52.4). The median progression-free survival for EGFR mutation-positive patients was 15 months (95% CI: 12.9–17.1), and the median relapse OS was 19 months (95% CI: 0.9–37.1). In addition, the 3- and 5-year postoperative survival rate was 51.9% and 15.3%, respectively. Conclusion: ASC patients harboring EGFR mutations had a good response to TKI therapy. Routine EGFR testing for ASCs was recommended. Further studies on TKI therapy versus chemotherapy alone for EGFR-mutant ASCs are required.